This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Darden University of Virginia (USA)
-
Balance-Statement Reporting at Premium Capital Funds (B)
Lopez-Jimenez, Liliana; Orozco, Luis Antonio; Gentile, MaryCase DARDEN-OB-1307-ELeadership and People ManagementThis case is part of the Giving Voice to Values (GVV) curriculum. To see other material in the GVV curriculum, please visit http://store.darden.virginia.edu/giving-voice-to-values. This B case contains a video and a transcript of an interview the case authors conducted with Ricardo Martinez on July 15, 2019, concerning his reflections on the ethical conflict described in the case and what he actually did about it.Starting at €5.74
-
Balance-Statement Reporting at Premium Capital Funds (A)
Lopez-Jimenez, Liliana; Orozco, Luis Antonio; Martinez-Gomez, Ricardo Emilio; Gentile, MaryCase DARDEN-OB-1306-ELeadership and People ManagementThis case is part of the Giving Voice to Values (GVV) curriculum. To see other material in the GVV curriculum, please visit http://store.darden.virginia.edu/giving-voice-to-values. In 2009, Ricardo Martinez, management assistant at Premium Capital Investment Advisors (PCIA), was asked to fabricate some of the information to be included in the monthly account balance statements addressed to five shareholders in Premium Capital Funds (Premium), a p...Starting at €8.20
-
Interbolsa’s Repo Trading: How to Stop an Insolvency Ticking Time Bomb (A)
Gentile, Mary; Lopez-Jimenez, Liliana; Arabia-Wartenberg, Jorge; Orozco, Luis AntonioCase DARDEN-OB-1356-ELeadership and People ManagementIn August 2004, Interbolsa’s risk management committee had to decide upon a request to double the authorized quota for repurchase agreements (repos) on Interbolsa’s own stock. Two months earlier, Jorge Arabia had joined Interbolsa, the largest stock brokerage firm in Colombia, as CFO. In this role, he had a seat in the risk management committee. Arabia had noticed that these repos carried large and diverse risks, not only for the firm but also f...Starting at €8.20
-
Interbolsa’s Repo Trading: How to Stop an Insolvency Ticking Time Bomb (B)
Gentile, Mary; Lopez-Jimenez, Liliana; Orozco, Luis AntonioCase DARDEN-OB-1357-ELeadership and People ManagementIn August 2004, Interbolsa’s risk management committee had to decide upon a request to double the authorized quota for repurchase agreements (repos) on Interbolsa’s own stock. Two months earlier, Jorge Arabia had joined Interbolsa, the largest stock brokerage firm in Colombia, as CFO. In this role, he had a seat in the risk management committee. Arabia had noticed that these repos carried large and diverse risks, not only for the firm but also f...Starting at €5.74
-
Balance-Statement Reporting at Premium Capital Funds (A) and (B) - Teaching Note
Lopez-Jimenez, Liliana; Martinez-Gomez, Ricardo Emilio; Orozco, Luis Antonio; Gentile, MaryTeaching Note DARDEN-OB-1306TN-ELeadership and People ManagementTeaching note for product OB-1306Starting at €0.00
-
Interbolsa’s Repo Trading: How to Stop an Insolvency Ticking Time Bomb (A) and (B) - Teaching Note
Gentile, Mary; Lopez-Jimenez, Liliana; Arabia-Wartenberg, Jorge; Orozco, Luis AntonioTeaching Note DARDEN-OB-1356TN-ELeadership and People ManagementTeaching Note for product OB-1356Starting at €0.00
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20